Medical Marijuana Analyst Coverage Initiated: Brief Report by BrokerBank Securities, Inc.

Oct 22, 2014, 07:00 ET from BrokerBank Securities, Inc.

NEW YORK, Oct. 22, 2014 /PRNewswire/ -- Medical Marijuana, Inc. (OTCBB: MJNA) operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company is targeting one big trend in medical marijuana: products that don't get you high. A large portion of the medical research going on is focused on the cannabinoids in Marijuana. There are 80+ of these cannabinoids in the cannabis plant and researchers think many of them may help medically with different things. 

MJNA services include development of cannabinoid based health and wellness products; and development of medical grade compounds; and licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. It also offers pre-and-post production tracking, gemplasm references, and packaging and processing services. These products are often expensive – companies making tinctures, capsules or creams infused with CBD-rich hemp must import the plant from outside the U.S. It's a process that is, not surprisingly, strictly regulated (translation: costly). But the market for these types of legal alternatives to marijuana may be growing. HempMeds – which makes CBD infused products – says they sell about $1 million in products each month. HempMeds' parent company, Medical Marijuana Inc. (MJNA), says that through all of its divisions, it's sold some $60 million worth of CBD-only, THC-free products so far this year. Medical Marijuana, Inc. is based in San Diego, California.

There has been considerable buzz as well as serious investor attention in the sector but also a tendency toward excess volatility and promotion.  As long as investors go in with eyes wide open this can be managed to advantage.  The recent decline appears to be exhausting – so be alert for an upward continuation and follow if to the upside with a $0.21 long target near term.

Refer to the analyst report for specific technical observations.  We would urge investors to conduct their own fundamental due diligence by at minimum, studying the Company's public disclosures.

An analyst report which details the current situation, technical analysis and analyst comments can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:

Copy and paste to browser may be required.

Forward-Looking Disclaimer   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Not Financial Advice

BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Compliance Procedure   

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.